CompleoTRT, which was submitted to the FDA earlier last year, is Trimel's most advanced product candidate, and is a bio-adhesive intra-nasal gel formulation of testosterone, designed to provide hypogonadal patients with a better alternative to current treatment options. Male hypogonadism is a condition in which the body doesn't produce enough testosterone — the hormone that plays a key role in masculine growth and development during puberty — or has an impaired ability to produce sperm or both.
Last month, Trimel said that following recent discussions with the FDA, it decided that the most expeditious way to seek approval of its treatment was to proceed with a proposed three-times-a-day dosing protocol, requiring a change to its proposed label to exclusively reflect this dosing regimen.
At the time the decision was announced, on December 19, Rossi said: "The company continues to believe that a twice-per-day dose represents a promising alternative for patients with hypogonadism and we are considering options for pursuing approval for such a dosing regimen."
http://www.proactiveinvestors.com/c...s-target-date-for-testosterone-nda-51354.html
Last month, Trimel said that following recent discussions with the FDA, it decided that the most expeditious way to seek approval of its treatment was to proceed with a proposed three-times-a-day dosing protocol, requiring a change to its proposed label to exclusively reflect this dosing regimen.
At the time the decision was announced, on December 19, Rossi said: "The company continues to believe that a twice-per-day dose represents a promising alternative for patients with hypogonadism and we are considering options for pursuing approval for such a dosing regimen."
http://www.proactiveinvestors.com/c...s-target-date-for-testosterone-nda-51354.html